Peregrine Capital Management LLC Sold 2,470 Shares of Natera Inc (NASDAQ:NTRA)

Peregrine Capital Management LLC Sold 2,470 Shares of Natera Inc (NASDAQ:NTRA)

Peregrine Capital Management LLC lessened its stake in shares of Natera Inc (NASDAQ:NTRA) by 0.5% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 533,483 shares of the medical research company’s stock after selling 2,470 shares during the period. Peregrine Capital Management LLC owned 0.86% of Natera worth $7,447,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Vanguard Group Inc grew its stake in Natera by 28.9% in the 3rd quarter. Vanguard Group Inc now owns 3,612,860 shares of the medical research company’s stock worth $86,493,000 after acquiring an additional 808,976 shares in the last quarter. Federated Investors Inc. PA bought a new position in Natera in the 3rd quarter worth about $797,000. Vanguard Group Inc. grew its stake in Natera by 28.9% in the 3rd quarter. Vanguard Group Inc. now owns 3,612,860 shares of the medical research company’s stock worth $86,493,000 after acquiring an additional 808,976 shares in the last quarter. Kepos Capital LP bought a new position in Natera in the 3rd quarter worth about $823,000. Finally, TIAA CREF Investment Management LLC grew its stake in Natera by 50.4% in the 3rd quarter. TIAA CREF Investment Management LLC now owns 314,241 shares of the medical research company’s stock worth $7,523,000 after acquiring an additional 105,355 shares in the last quarter. 87.50% of the stock is owned by institutional investors and hedge funds.

NTRA has been the topic of a number of research analyst reports. Cowen restated a “buy” rating and issued a $30.00 target price on shares of Natera in a research note on Friday, November 9th. ValuEngine downgraded shares of Natera from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, January 9th. BidaskClub upgraded shares of Natera from a “strong sell” rating to a “sell” rating in a research note on Friday, December 7th. Finally, Zacks Investment Research downgraded shares of Natera from a “hold” rating to a “sell” rating in a research note on Thursday, January 10th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $28.25.

NTRA traded up $0.47 during trading on Monday, hitting $15.22. The stock had a trading volume of 298,446 shares, compared to its average volume of 617,966. The company has a market cap of $911.90 million, a price-to-earnings ratio of -6.34 and a beta of 1.79. Natera Inc has a twelve month low of $8.60 and a twelve month high of $29.62. The company has a quick ratio of 2.32, a current ratio of 2.44 and a debt-to-equity ratio of 1.30.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, November 8th. The medical research company reported ($0.49) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.03). The firm had revenue of $65.30 million during the quarter, compared to analyst estimates of $66.42 million. Natera had a negative net margin of 58.00% and a negative return on equity of 2,569.52%. Natera’s revenue was up 16.8% on a year-over-year basis. During the same quarter last year, the business earned ($0.51) earnings per share. On average, sell-side analysts expect that Natera Inc will post -2.12 EPS for the current year.

Natera Profile

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Recommended Story: What is the S&P 500 Index?

Related posts

Leave a Comment